|
1
|
Ain KB: Anaplastic thyroid carcinoma: A
therapeutic challenge. Semin Surg Oncol. 16:64–69. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Demeter JG, De Jong SA, Lawrence AM and
Paloyan E: Anaplastic thyroid carcinoma: risk factors and outcome.
Surgery. 110:956–961. 1991.PubMed/NCBI
|
|
3
|
Hundahl SA, Fleming ID, Fremgen AM and
Menck HR: A National Cancer Data Base report on 53,856 cases of
thyroid carcinoma treated in the U.S., 1985–1995 [see commetns].
Cancer. 83:2638–2648. 1998. View Article : Google Scholar
|
|
4
|
Kebebew E, Greenspan FS, Clark OH, Woeber
KA and McMillan A: Anaplastic thyroid carcinoma. Treatment outcome
and prognostic factors. Cancer. 103:1330–1335. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nel CJ, van Heerden JA, Goellner JR,
Gharib H, McConahey WM, Taylor WF and Grant CS: Anaplastic
carcinoma of the thyroid: A clinicopathologic study of 82 cases.
Mayo Clin Proc. 60:51–58. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tan RK, Finley RK III, Driscoll D,
Bakamjian V, Hicks WL Jr and Shedd DP: Anaplastic carcinoma of the
thyroid: A 24-year experience. Head Neck. 17:41–47; discussion
47–48. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Venkatesh YS, Ordonez NG, Schultz PN,
Hickey RC, Goepfert H and Samaan NA: Anaplastic carcinoma of the
thyroid. A clinicopathologic study of 121 cases. Cancer.
66:321–330. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Voutilainen PE, Multanen M, Haapiainen RK,
Leppäniemi AK and Sivula AH: Anaplastic thyroid carcinoma survival.
World J Surg. 23:975–978; discussion 978–979. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shaha AR: Implications of prognostic
factors and risk groups in the management of differentiated thyroid
cancer. Laryngoscope. 114:393–402. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nagaiah G, Hossain A, Mooney CJ,
Parmentier J and Remick SC: Anaplastic thyroid cancer: A review of
epidemiology, pathogenesis, and treatment. J Oncol.
2011:5423582011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Marino N and Zollo M: Understanding
h-prune biology in the fight against cancer. Clin Exp Metastasis.
24:637–645. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zollo M, Andrè A, Cossu A, Sini MC,
D'Angelo A, Marino N, Budroni M, Tanda F, Arrigoni G and Palmieri
G: Overexpression of h-prune in breast cancer is correlated with
advanced disease status. Clin Cancer Res. 11:199–205.
2005.PubMed/NCBI
|
|
13
|
Oue N, Yoshida K, Noguchi T, Sentani K,
Kikuchi A and Yasui W: Increased expression of h-prune is
associated with tumor progression and poor survival in gastric
cancer. Cancer Sci. 98:1198–1205. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Noguchi T, Oue N, Wada S, Sentani K,
Sakamoto N, Kikuchi A and Yasui W: h-Prune is an independent
prognostic marker for survival in esophageal squamous cell
carcinoma. Ann Surg Oncol. 16:1390–1396. 2009. View Article : Google Scholar
|
|
15
|
Kobayashi T, Hino S, Oue N, Asahara T,
Zollo M, Yasui W and Kikuchi A: Glycogen synthase kinase 3 and
h-prune regulate cell migration by modulating focal adhesions. Mol
Cell Biol. 26:898–911. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
The Japanese Society of Thyroid Surgery:
General Rules for the Description of Thyroid Cancer. 6th edition.
Kanehara Press; Tokyo, Japan: 2005
|
|
17
|
Kurebayashi J, Okubo S, Yamamoto Y, Ikeda
M, Tanaka K, Otsuki T and Sonoo H: Additive antitumor effects of
gefitinib and imatinib on anaplastic thyroid cancer cells. Cancer
Chemother Pharmacol. 58:460–470. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Forus A, D'Angelo A, Henriksen J, Merla G,
Maelandsmo GM, Flørenes VA, Olivieri S, Bjerkehagen B, Meza-Zepeda
LA, del Vecchio Blanco F, et al: Amplification and overexpression
of PRUNE in human sarcomas and breast carcinomas - a possible
mechanism for altering the nm23-H1 activity. Oncogene.
20:6881–6890. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
D'Angelo A, Garzia L, André A, Carotenuto
P, Aglio V, Guardiola O, Arrigoni G, Cossu A, Palmieri G, Aravind
L, et al: Prune cAMP phosphodiesterase binds nm23-H1 and promotes
cancer metastasis. Cancer Cell. 5:137–149. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Steeg PS: Metastasis suppressors alter the
signal transduction of cancer cells. Nat Rev Cancer. 3:55–63. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Carotenuto M, De Antonellis P, Liguori L,
Benvenuto G, Magliulo D, Alonzi A, Turino C, Attanasio C, Damiani
V, Bello AM, et al: H-Prune through GSK-3β interaction sustains
canonical WNT/β-catenin signaling enhancing cancer progression in
NSCLC. Oncotarget. 5:5736–5749. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Müller T, Stein U, Poletti A, Garzia L,
Rothley M, Plaumann D, Thiele W, Bauer M, Galasso A, Schlag P, et
al: ASAP1 promotes tumor cell motility and invasiveness, stimulates
metastasis formation in vivo, and correlates with poor survival in
colorectal cancer patients. Oncogene. 29:2393–2403. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lin D, Watahiki A, Bayani J, Zhang F, Liu
L, Ling V, Sadar MD, English J, Fazli L, So A, et al: ASAP1, a gene
at 8q24, is associated with prostate cancer metastasis. Cancer Res.
68:4352–4359. 2008. View Article : Google Scholar : PubMed/NCBI
|
